{
  "metadata": {
    "source_file": "pdfs/Comparison of Rapid Antigen Tests for COVID-19.pdf",
    "extraction_method": "enhanced_column_detection",
    "extraction_date": "2025-10-02T00:06:37.864303",
    "total_pages": 8,
    "total_characters": 27052,
    "total_words": 4364
  },
  "content": {
    "full_text": "--- Page 1 ---\nviruses\nArticle\nComparison of Rapid Antigen Tests for COVID-19\n1 1, , Yuko Sakai-Tagawa Seiya Yamayoshi *\n5 6 Ichiro Nakachi , Hidefumi Koh , Kenji Maeda\n3 2,3 Hiroyuki Nagai , Kazuhiko Ikeuchi , Takayuki Ogura\n6 6 Takahiro Fukui , Fumimaro Ito , Shin-ichiro Hattori\n1 1 Yuri Furusawa , Atsuhiro Yasuhara , Michiko Ujie\n7 9 Hiroaki Mitsuya , Norio Omagari , Hiroshi Yotsuyanagi\n1 1,10,11, Masaki Imai and Yoshihiro Kawaoka *\n1 Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science,\nThe University of Tokyo, Tokyo 108-8639, Japan; ytsakai@g.ecc.u-tokyo.ac.jp (Y.S.-T.);\nkk187321@stu-cbms.k.u-tokyo.ac.jp (Y.F.); yasuhara@ims.u-tokyo.ac.jp (A.Y.);\nkenken@ims.u-tokyo.ac.jp (K.I.-H.); mimai@ims.u-tokyo.ac.jp (M.I.)\n2 Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science,\nThe University of Tokyo, Tokyo 108-8639, Japan; michiko@ims.u-tokyo.ac.jp (M.K.);\nsaito-id@ims.u-tokyo.ac.jp (M.S.); kikeuchi004@gmail.com (K.I.); yotsudid@ims.u-tokyo.ac.jp (H.Y.)\n3\nScience, The University of Tokyo, Tokyo 108-8639, Japan; e-adachi@ims.u-tokyo.ac.jp (E.A.);\nnagai.hir@gmail.com (H.N.)\n4\n5 Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital,\nTochigi 321-0974, Japan; nichiro4747@gmail.com (I.N.); rie.amechan@gmail.com (R.B.)\n6 Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital,\nTokyo 190-8531, Japan; h.koh@tachikawa-hosp.gr.jp (H.K.); ftakahiro0529@yahoo.co.jp (T.F.);\nﬁto102351@gmail.com (F.I.)\n7 Department of Refractory Viral Infections, National Center for Global Health and Medicine Research\nInstitute, Tokyo 162-8655, Japan; kmaeda@ri.ncgm.go.jp (K.M.); shattori@ri.ncgm.go.jp (S.-i.H.);\nhmitsuya@hosp.ncgm.go.jp (H.M.)\n8 Department of Emergency Medicine and Critical Care Medicine, Saiseikai Utsunomiya Hospital,\nTochigi 321-0974, Japan; alongthelongestway2003@yahoo.co.jp (T.O.); fujitak.727@gmail.com (K.F.)\n9 Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital,\nTokyo 162-8655, Japan; kyamamoto@hosp.ncgm.go.jp (K.Y.); tnakamoto@hosp.ncgm.go.jp (T.N.);\nnohmagari@hosp.ncgm.go.jp (N.O.)\n10\nMadison, WI 53706, USA\n11\nScience, The University of Tokyo, Tokyo 108-8639, Japan\n* Correspondence: yamayo@ims.u-tokyo.ac.jp (S.Y.); yoshihiro.kawaoka@wisc.edu (Y.K.)\nù Academic Editor: Giorgio Pal\nReceived: 12 November 2020; Accepted: 8 December 2020; Published: 10 December 2020\nAbstract:\n/ Viruses 12 2020 , , 1420; doi:10.3390 v12121420\n\n2,3 4 , Michiko Koga , Osamu Akasaka ,\n7 3 2,3 , Eisuke Adachi , Makoto Saito ,\n8 5 8 , Rie Baba , Kensuke Fujita ,\n7 9 9 , Kei Yamamoto , Takato Nakamoto ,\n1 1 1 , Shinya Yamada , Mutsumi Ito ,\n2,3 1 , Kiyoko Iwatsuki-Horimoto ,\nm-ujie@ims.u-tokyo.ac.jp (M.U.); syamada@g.ecc.u-tokyo.ac.jp (S.Y.); ito-mu@ims.u-tokyo.ac.jp (M.I.);\nDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of Institute of Medical\nEmergency Medical Center, Fujisawa City Hospital, Kanagawa 251-8550, Japan; samukun036@gmail.com\nDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison,\nInternational Research Center for Infectious Diseases, Department of Special Pathogens, Institute of Medical\n\u0001\u0002\u0003\u0001\u0004\u0005\u0006\u0007\b\n\u0001\u0002\u0003\u0004\u0005\u0006\u0007\nReverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose\ncoronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local clinics where\nRT-qPCR testing capability is lacking, rapid antigen tests (RATs) for COVID-19 based on lateral ﬂow\nimmunoassays are used for rapid diagnosis. However, their sensitivity compared with each other\nand with RT-qPCR and infectious virus isolation has not been examined. Here, we compared the\nsensitivity among four RATs by using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\nisolates and several types of COVID-19 patient specimens and compared their sensitivity with that\nof RT-qPCR and infectious virus isolation. Although the RATs read the samples containing large\n/ / www.mdpi.com journal viruses\n\n--- Page 2 ---\nViruses 12 2020 , , 1420\nare shedding infectious SARS-CoV-2.\nKeywords: rapid antigen test; diagnosis; COVID-19; SARS-CoV-2\n1. Introduction\n1 pathogen in China at the end of 2019 [\ncauses symptoms such as cough and fever, severe pneumonia, and death. The WHO reported that\n// / 16 September 2020 ( https: covid19.who.int\nidentiﬁcation and isolation of patients are required.\nusing nasopharyngeal (N) swabs, throat (T) swabs, or saliva [\nRNA extraction and high-throughput RT-qPCR systems have been developed. Although such tests are\nwidely utilized in public health laboratories and large well-equipped hospitals, they are unavailable\nin local clinics where patients who suspect they have COVID-19 often go ﬁrst. Therefore, specimens\nresult and increases the anxiety of the suspected COVID-19 patients. To improve this situation, rapid\nantigen tests (RATs) for COVID-19, which does not require speciﬁc and expensive machinery, have\nbeen approved for clinical use in Japan and other countries, and the sensitivity of these tests has been\ncompared with that of several kinds of RT-qPCR [\nthe detection of isolated viruses. We also evaluated their e\n2. Materials and Methods\n2.1. Ethics and Biosafety Statements\n1 February 2020). Signed informed consent was obtained from all participants.\n(BSL3) laboratories at the University of Tokyo, which were approved for such use by the Ministry of\nAgriculture, Forestry, and Fisheries, Japan.\n2.2. Cells\nVero cells expressing human serine protease TMPRSS2 (Vero-TMPRSS2) [\nin DMEM containing 10% fetal calf serum (FCS), 1 mg\n/ µ streptomycin, and 5 g\n◦\nat 37 C under 5% CO . We used these cells after clearance of mycoplasma.\n2\n\n2 of 8\namounts of virus as positive, even the most sensitive RAT read the samples containing small amounts\nof virus as negative. Moreover, all RATs tested failed to detect viral antigens in several specimens\nfrom which the virus was isolated. The current RATs will likely miss some COVID-19 patients who\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged as a novel human\n], is responsible for coronavirus disease 2019 (COVID-19), which\nmore than 29 million cases of COVID-19, including approximately 900,000 deaths, have occurred as of\n). To control the spread of SARS-CoV-2 infections, rapid\nThe gold standard for COVID-19 diagnosis is reverse transcription-quantitative PCR (RT-qPCR)\n2 ]. RT-qPCR kits that do not require viral\nneed to be transported to and examined at sites that have RT-qPCR capability, which delays the test\n– ]. Although these RATs might be useful for 3 9\nthe identiﬁcation of COVID-19 patients in local clinics, their sensitivity is important in determining\nusage strategies. Here, we examined the sensitivity of four RATs available in Japan in August 2020 for\nﬀ ectiveness with several kinds of clinical\nspecimens collected from COVID-19 patients and compared it with that of RT-qPCR and virus isolation.\nHuman samples were collected by following protocols approved by the Research Ethics Review\nCommittee of the Institute of Medical Science, the University of Tokyo (approval number 2019-71-0201;\nAll experiments with SARS-CoV-2 were performed prior to 8 September 2020 in biosafety level 3\n] were maintained 10\n/ / / µ mL G418, 100 units mL penicillin, 100 g mL\nmL plasmocin prophylactic (InvivoGen, San Diego, CA, USA) and incubated\n\n--- Page 3 ---\nViruses 12 2020 , , 1420\n2.3. Viruses\n/ / / SARS-CoV-2 (UT-NCGM02 Human 2020\n(HP72)] were isolated from clinical samples collected in February and August, respectively, and titrated\nin Vero-TMPRSS2 cells by performing plaque assays [\n2.4. Clinical Samples\n= = n n Gargle lavage ( 7), saliva (\n= N n n nasopharyngeal ( ) swab ( 18), sputum (\n( Supplementary Materials Table S1\naspirate samples were diluted in BD universal viral transport medium if needed. These media were\nused as test specimens. Gargle lavages were examined directly.\n2.5. RT-qPCR\nTokyo, Japan) according to the protocol of the National Institute of Infectious Disease, Japan [\n> value of 40 was considered a negative result.\n2.6. Rapid Antigen Test (RAT)\nThe RATs listed in Table 1\nmanufacturers’ instructions, using 75–7500 plaque formation unit (PFU) of stock virus in 50\nµ of culture supernatant or 50\neach sample.\nTable 1.\nName Manufacturer\nStandard Q COVID-19 Ag SD Biosensor\nEspline SARS-CoV-2 Fujirebio\nQuickNavi -COVID19 Ag Denka Seiken\nImmunoAce SARS-CoV-2 Tauns Laboratories\nThe lysed sample is dropped into the well and the reaction occurs inside a covered plastic body. a\nµ antigen tests (RATs) tested, the test samples (50\nwas then assayed. Input ratios were calculated using the following formula: volume B\nThe time required to obtain the results is based on the manufacturer’s instructions provided with the kit. c\n2.7. Virus Isolation\n◦\nincubated at 37\n/ µ 5% FCS, 10 mM HEPES, 100 g mL gentamicin sulfate, and 2.5\n◦\nﬀ 37 C. The appearance of cytopathic e\n3. Results\n3.1. Comparison of 4 Rapid Antigen Tests (RATs)\nWe evaluated four RATs that were available in Japan in August 2020 (Table\nimmunochromatographic tests; therefore, their sensitivity is dependent on the binding kinetics of\nthe monoclonal antibodies used in each RAT. The composition of the lysis bu\nof specimen in the analyte, and the method used to visualize the result also a\nAs a result that the manufacturers do not disclose the composition of the lysis bu\n\n3 of 8\n/ / / Tokyo (NC02) and UT-HP072 Human 2020 Tokyo\n11 ].\n= = n n 27), throat (T) swab ( 2), nasal vestibule swab ( 1),\n= = n 4), and tracheal aspirate ( 17) samples\n) were collected from COVID-19 patients at several timepoints\nafter onset. Swabs were soaked in BD universal viral transport medium; saliva, sputum, and tracheal\nViral RNA was isolated from the specimens by using the QIAamp Viral RNA Mini Kit (QIAGEN,\nTokyo, Japan). One step RT-qPCR was performed using the LightCycler 96 System (Roche Diagnostics,\n12 ]. A Cq\nwere evaluated according to the procedures described in the\nµ L\nL of specimen. Two independent experiments were performed with\nRapid antigen tests examined in this study.\nMethod for Input Ratio Country of Minutes to\n(%) a b c Visualization Assess Manufacture\nColor particle 14.3 15–30 Korea\nAlkaline phosphatase 10.0 30 Japan\nColor latex 12.5 15 Japan\nPlatinum-gold colloid 28.6 15 Japan\nFor all rapid b\nﬀ L) were mixed with lysis bu er (A). A part of the lysed sample (B)\n× / + µ (50 L volume A) 100.\nThe specimens were inoculated into Vero-TMPRSS2 cells in 24 well-plates and the cells were\nC for 1 h. After removal of the inoculum, the cells were incubated in DMEM containing\n/ µ g mL amphotericin B for 6 days at\nects was checked for 6 days at least once a day.\n1 ). These RATs are\nﬀ er, the proportion\nﬀ ect the sensitivity.\nﬀ er, we could not\n\n--- Page 4 ---\nViruses 12 2020 , , 1420\nﬀ compare this parameter. The amount of lysis bu\nﬀ di ered among the RATs tested. Accordingly, the percentages of the specimens used also di\nfor Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce\n(Table 1 ). The method for visualization of the results also di\nQ COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce SARS-CoV-2\nrespectively, to visualize the antigen-antibody immune-complexes. The visualized results are assessed\nby the human eye at 15–30, 30, 15, and 15 min, respectively, after adding the analyte. Although the\n(see the footnote to Tables 2 and 3 ).\nTable 2.\nNumber of Standard Q RT-qPCR\na Samples COVID-19 Ag (Cq Value)\nb –20.0 4 4\n20.0–22.5 7 7\n22.5–25.0 17 10.5\n25.0–27.5 20 2.5\n27.5–30.0 17 2\n30.0– 11 0\na\nb 4 sputum, and 17 tracheal aspirates were examined.\nwhen a kit identiﬁed a sample as positive in both tests, a value of 1 was assigned. If only one test was positive, a\nvalue of 0.5 was assigned. If both tests were negative, a value of 0 was assigned.\nthe virus was isolated.\nTable 3. Sensitivity of rapid antigen tests for di\nNumber of Standard Q RT-qPCR\nClinical Specimen\nSamples COVID-19 Ag (Cq Value)\na Gargle lavage 7 26.3–36.0 0\nSaliva 27 18.8–33.0 10\nc 25.8 T Swab 2 , 33.6 0\nNasal vestibule swab 1 34.8 0\nN swab 18 19.7-33.0 8\nSputum 4 19.9-34.3 1\nTracheal aspirate 17 19.6-35.6 7\na\nb negative, a value of 0 was assigned.\nthis specimen.\n3.2. Sensitivity of RATs for Two Isolated SARS-CoV-2 Strains\nwere diluted to the indicated PFU and then examined by RT-qPCR to determine the Cq value of each\nand 16.9, 17.8, 18.8, 20.4, 21.1, 22.7, and 24.0 at 7500, 5000, 2500, 750, 500, 250, and 75 PFU of HP72\n(Table S2). Standard Q COVID-19 Ag and ImmunoAce SARS-CoV-2 detected as little as 250 PFU of\nNC02, respectively (Table S2). Standard Q COVID-19 Ag and Espline SARS-CoV-2 detected as little as\n250 PFU of HP72, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 detected 5000 PFU\nﬀ ImmunoAce SARS-CoV-2 di ered depending on the isolate.\n\n4 of 8\n/ ﬀ er and specimen lysis bu er mixture used for testing\nﬀ ered:\nSARS-CoV-2, the percentages of specimens used were 14.3%, 10.0%, 12.5%, and 28.6%, respectively\nﬀ ered among these tests in that Standard\nuse color particles, alkaline phosphatase and its substrate, color latex, and platinum-gold colloids,\ntypes of specimens recommended for all four RATs are N swabs, we tested other types of specimens\nSensitivity of rapid antigen tests for clinical specimens.\nQuickNavi ImmunoAce Virus Espline\nCOVID19 Ag SARS-CoV-2 Isolation SARS-CoV-2\nc 4 3.5 3.5 2\n7 4.5 6 6\n12.5 5 9.5 9\n3 2 3.5 4\n1 0 2 3\n0 0 0 0\nA total of 76 clinical specimens including 7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs,\nEach sample was tested in two independent experiments;\nc Number of samples from which\nﬀ erent types of clinical specimen.\nQuickNavi ImmunoAce Virus Espline\nCOVID19 Ag SARS-CoV-2 Isolation SARS-CoV-2\nb 0 0 0 0\n12 5 13 12\n0 0 0 1\n0 0 0 0\n8 3.5 7 10\n1 1 1 0\n6.5 5.5 3.5 1\nEach specimen was tested in two independent experiments; when a kit identiﬁed a sample as positive in both\ntests, a value of 1 was assigned. If only one test was positive, a value of 0.5 was assigned. If both tests were\nc Number of samples from which virus was isolated. Virus was isolated from\nTo compare the sensitivity of these four RATs, two SARS-CoV-2 isolate stocks (NC02 and HP72)\nsample. The Cq values were 18.0, 21.7, 22.2, 23.1, and 25.4 at 7500, 750, 500, 250, and 75 PFU of NC02\nNC02, whereas Espline SARS-CoV-2 and QuickNavi -COVID19 Ag detected 500 PFU and 750 PFU of\nof HP72. These results show that the sensitivity for virus detection of Standard Q COVID-19 Ag and\nEspline SARS-CoV-2 was better than that of QuickNavi COVID19 Ag, and that virus detection by\n\n--- Page 5 ---\nViruses 12 2020 , , 1420\n3.3. Sensitivity of RATs for Clinical Specimens\n(T) swabs, 1 nasal vestibule swabs, 18 nasopharyngeal (N) swabs, 4 sputum, and 17 tracheal aspirates\nwere collected and their viral genomic RNA levels were examined by RT-qPCR. These 76 clinical\nRATs and subjected to virus isolation using Vero-TMPRSS2 cells (Table\nQ COVID-19 Ag and Espline SARS-CoV-2 detected viral antigens in all specimens with Cq values\nlower than 22.5, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 failed to detect\nthe sensitivity was on the order of Espline SARS-CoV-2, Standard Q COVID-19 Ag, ImmunoAce\nSARS-CoV-2, and QuickNavi COVID19 Ag (Table\nvalue greater than 25.0, the sensitivity of these four RATs was similar. These results indicate that the\nImmunoAce SARS-CoV-2; QuickNavi -COVID19 Ag had the lowest sensitivity.\nof days after onset that the specimens were obtained, and the Cq values of the RT-qPCR (Figure\nﬃ Although all of the RATs e\nﬀ results from the RATs could be di\nRAT-positive, whereas others were RAT-negative). Several specimens with Cq values higher than those\ncyan arrows in Figure 1\nﬀ protein content may have di\ninhibitors or enhancers for the antigen-antibody reaction of the RATs. Importantly, several specimens\nfrom which the virus was isolated were negative with all RATs tested, indicating that these RATs could\npotentially fail to diagnose patients shedding infectious SARS-CoV-2.\nFigure 1.\nand 17 tracheal aspirates) were examined by Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi\nCOVID19 Ag, and ImmunoAce SARS-CoV-2. Two independent experiments were performed.\n\n5 of 8\nTo evaluate the sensitivity of the four RATs for clinical specimens, 7 gargle lavages, 27 saliva, 2 throat\nspecimens, which were divided into 6 groups based on their Cq value, were examined in the four\n2 and Table S1). Standard\nviral antigens in several of these specimens. For specimens with a Cq value between 22.5 and 25.0,\n2 and Table S1). For the specimens with a Cq\nsensitivity of the four RATs is lower than that of RT-qPCR but similar to that of virus isolation. Overall,\nthe sensitivity of Espline SARS-CoV-2 and Standard Q COVID-19 Ag was slightly better than that of\nWe next plotted the results from the RATs and virus isolation, in accordance with the number\n1 ).\nciently detected viral antigens in the specimens with low Cq values, the\nerent for two specimens with similar Cq values (i.e., some were\nof specimens that were RAT-negative, but with the above-described low Cq values (as indicated by\n) were found to be RAT-positive. These results suggest that the viral RNA and\nered between the specimens or that some samples may have contained\nResults of RATs plotted based on the Cq value of RT-qPCR and days after onset. Viral antigens in\n76 clinical specimens (7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs, 4 sputum,\n\n--- Page 6 ---\nViruses 12 2020 , , 1420\nspecimens from which virus was isolated; open black circles indicate specimens from which virus was\none was positive, no color indicates both were negative.\nﬀ Since the type of specimen likely a\nand nasal vestibule swabs showed higher Cq values than the other types of specimens (Table\nAll four RATs detected virus antigens in one sputum sample, although no virus was isolated from\nand 1 nasal vestibule swabs, although the virus was isolated from one T swab sample. Since N swabs\nand saliva are suitable specimens for diagnosis in clinics, we plotted the results from the RATs and\nvirus isolation based on the number of days after onset that the specimens were collected and the Cq\nvalues of the RT-qPCR (Figure 2\nﬃ SARS-CoV-2 e\nthat were collected at early timepoints after onset.\nFigure 2.\nand days after onset. The results from the N swabs and saliva samples were extracted from Figure\n\n6 of 8\nAll specimens were also tested by RT-qPCR and subjected to virus isolation. Open red circles indicate\nnot isolated. Circles ﬁlled in black indicate both results were positive, those ﬁlled in gray indicate that\nects the sensitivity of RATs, we assessed our results according\nto specimen type (gargle lavage, saliva, T swab, nasal vestibule swab, N swab, sputum, and tracheal\naspirate). Although the Cq value varied between specimens from 18.8 to 36.0, gargle lavage, T swabs,\n3 ).\n4 sputum samples tested. All four RATs failed to detect virus antigens in all 7 gargle lavages, 2 T swabs,\n). Standard Q COVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce\n< ciently detected virus antigens in N swabs and saliva with low Cq values (Cq 25)\nResults of RATs using N swabs and saliva specimens plotted based on the Cq value of RT-qPCR\n1 .\n\n--- Page 7 ---\nViruses 12 2020 , , 1420\n4. Discussion\nSARS-CoV-2 and QuickNavi COVID19 Ag. For specimens such as saliva and swabs, Standard Q\nThese three kits detected viral antigens in more than half of the specimens whose Cq values of RT-qPCR\nwere less than approximately 25. Therefore, these RATs may be suitable for the detection of COVID-19\npatients with a high likelihood of transmitting the virus to others.\nThis ﬁnding indicates that the current RATs are likely to miss some COVID-19 patients who are\nvirus to others. Further studies are required to address this point. In addition, the present study used\nﬀ bu\nisolated gave negative results with all of the RATs tested here. Nonetheless, these RATs need to be\nimproved with respect to their sensitivity.\nrates of these kits. Therefore, studies on false-positive rates should be performed in the future to\ndetermine the speciﬁcity of these and other RATs.\nSupplementary Materials: The following are available online at\nTable S1: List of specimens and results, Table S2: Sensitivity of rapid antigen tests for stock viruses.\nAuthor Contributions:\n(Seiya Yamayoshi) and Y.K. analyzed the data. S.Y. (Seiya Yamayoshi) and Y.K. wrote the manuscript. All authors\nhave read and agreed to the published version of the manuscript.\nFunding:\nJP20nk0101614, and JP20nk0101603), the Japan Initiative for Global Research Network on Infectious\nDiseases (J-GRID) (JP19fm0108006), and a Japan Program for Infectious Diseases Research and Infrastructure\n(JP20wm0125002) from the Japan Agency for Medical Research and Development (AMED), and the National\nHHSN272201400008C).\nAcknowledgments:\nof experiments and Susan Watson for editing the manuscript.\nConﬂicts of Interest:\nReferences\n1.\nN. Engl. J. Med. from Patients with Pneumonia in China, 2019.\nSethuraman, N.; Jeremiah, S.S.; Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. 2.\n2249–2251. [ CrossRef ] [ PubMed ]\n3.\nJ. Clin. Microbiol. Antigen Test to Diagnose COVID-19.\n\n7 of 8\nHere we evaluated the sensitivity of four RATs available in Japan in August 2020. The overall\nsensitivity of Standard Q COVID-19 Ag and Espline SARS-CoV-2 was better than that of ImmunoAce\nCOVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce SARS-CoV-2 had similar detection sensitivities.\nin individuals who are shedding a large amount of SARS-CoV-2; that is, they may be useful to identify\nAll four RATs failed to detect viral antigens in several specimens from which virus was isolated.\nshedding infectious SARS-CoV-2. However, it is unclear to what extent such patients would transmit\nswab specimens that were soaked in transport medium; if the specimens were directly soaked in lysis\ner, the sensitivity of the RATs might be improved. The recommended samples for these RATS\nare nasopharyngeal swabs not saliva, and some of the saliva samples from which SARS-CoV-2 was\nIn this study, we focused on the sensitivity of four RATs; we did not evaluate the false-positive\n// / / / / / http: www.mdpi.com 1999-4915 12 12 1420 s1 ,\nS.Y. (Seiya Yamayoshi) and Y.K. designed the study. S.Y. (Seiya Yamayoshi) and Y.S.-T.\nperformed the experiments. M.K., H.M., O.A., I.N., H.K., K.M., E.A., M.S., H.N., K.I., T.O., R.B., K.F., T.F., F.I., S.-i.H.,\nK.Y., T.N., Y.F., N.O., H.M., and H.Y. collected the clinical samples. A.Y., M.U., and S.Y. (Shinya Yamada) assisted\nwith the experiments. M.I. (Mutsumi Ito), K.I.-H., and M.I. (Masaki Imai) assisted with the sample collection. S.Y.\nThis work was supported by a Research Program on Emerging and Re-emerging Infectious\nDiseases (JP19fk0108113 and JP19fk0108166), a Project Promoting Support for Drug Discovery (JP20nk0101612,\nInstitutes of Allergy and Infectious Diseases funded Center for Research on Inﬂuenza Pathogenesis (CRIP;\nWe thank Noriko Kinoshita, Shigehiro Hagiwara, Daisuke Arai, Hidenori Takahashi, Genta\nNagao, and Shunichiro Konishi, Hiroko Shibata, Osamu Takahashi, Takashi Momoda, Hiromi Isshiki for assistance\nYoshihiro Kawaoka obtained funds to organize a symposium, “Inﬂuenza and Other\nInfections” in 2019 from TAUNS Laboratories, Inc. Kei Yamamoto has received grant support from Fujirebio, Inc.\nZhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus\n382 2020 , , 727–733. [ CrossRef ] [ PubMed ]\nJAMA 323 2020 , ,\nNagura-Ikeda, M.; Imai, K.; Tabata, S.; Miyoshi, K.; Murahara, N.; Mizuno, T.; Horiuchi, M.; Kato, K.; Imoto, Y.;\nIwata, M.; et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR\n(RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Ampliﬁcation, and a Rapid\n58 2020 , , e01438-20. [ CrossRef ] [ PubMed ]\n\n--- Page 8 ---\nViruses 12 2020 , , 1420\n4.\nrapid antigen test for detection of SARS-CoV-2 virus.\nﬀ Lambert-Niclot, S.; Cu 5.\nﬀ Le Go\nJ. Clin. Microbiol. 2020 in Nasopharyngeal Swabs. ,\n6.\nInt. J. Infect. Dis. 99 2020 in respiratory samples. ,\n7.\nperformance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.\n129 , 104455. [ CrossRef ] [ PubMed ]\n8.\nﬀ Melin, P.; Sto\nFront. Med. (Lausanne) Assay in a Pandemic Context.\n9.\na laboratory without access to molecular methods: Experiences of a general hospital.\n104472. [ CrossRef ] [ PubMed ]\n10.\nKato, F.; et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.\n117 2020 , , 7001–7003. [ CrossRef ] [ PubMed ]\n11.\nProc. Natl. Acad. Sci. USA countermeasure development.\n12.\nJpn. J. Infect. Dis. 73 2020 in Japan. , , 304–307. [\nPublisher’s Note:\nﬃ a liations.\n©\n// (CC BY) license (http:\n\n8 of 8\nMak, G.C.; Cheng, P.K.; Lau, S.S.; Wong, K.K.; Lau, C.S.; Lam, E.T.; Chan, R.C.; Tsang, D.N. Evaluation of\nJ. Clin. Virol. 129 2020 , , 104500. [ CrossRef ] [ PubMed ]\nel, A.; Le Pape, S.; Vauloup-Fellous, C.; Morand-Joubert, L.; Roque-Afonso, A.M.;\n, J.; Delaugerre, C. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen\n58 , e00977-20. [ CrossRef ] [ PubMed ]\nPorte, L.; Legarraga, P.; Vollrath, V.; Aguilera, X.; Munita, J.M.; Araos, R.; Pizarro, G.; Vial, P.; Iruretagoyena, M.;\nDittrich, S.; et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2\n, 328–333. [ CrossRef ] [ PubMed ]\nScohy, A.; Anantharajah, A.; Bodeus, M.; Kabamba-Mukadi, B.; Verroken, A.; Rodriguez-Villalobos, H. Low\nJ. Clin. Virol. 2020 ,\nMertens, P.; De Vos, N.; Martiny, D.; Jassoy, C.; Mirazimi, A.; Cuypers, L.; Van den Wijngaert, S.; Monteil, V.;\nels, K.; et al. Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic\n7 2020 , , 225. [ CrossRef ] [ PubMed ]\nBlairon, L.; Wilmet, A.; Beukinga, I.; Tre-Hardy, M. Implementation of rapid SARS-CoV-2 antigenic testing in\nJ. Clin. Virol. 129 2020 , ,\nMatsuyama, S.; Nao, N.; Shirato, K.; Kawase, M.; Saito, S.; Takayama, I.; Nagata, N.; Sekizuka, T.; Katoh, H.;\nProc. Natl. Acad. Sci. USA\nImai, M.; Iwatsuki-Horimoto, K.; Hatta, M.; Loeber, S.; Halfmann, P.J.; Nakajima, N.; Watanabe, T.; Ujie, M.;\nTakahashi, K.; Ito, M.; et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and\n117 2020 , , 16587–16595. [ CrossRef ] [ PubMed ]\nShirato, K.; Nao, N.; Katano, H.; Takayama, I.; Saito, S.; Kato, F.; Katoh, H.; Sakata, M.; Nakatsu, Y.; Mori, Y.;\net al. Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019)\nCrossRef ] [ PubMed ]\nMDPI stays neutral with regard to jurisdictional claims in published maps and institutional\n2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access\narticle distributed under the terms and conditions of the Creative Commons Attribution\n/ / / / creativecommons.org licenses by 4.0 ).",
    "pages": [
      {
        "page_number": 1,
        "text": "viruses\nArticle\nComparison of Rapid Antigen Tests for COVID-19\n1 1, , Yuko Sakai-Tagawa Seiya Yamayoshi *\n5 6 Ichiro Nakachi , Hidefumi Koh , Kenji Maeda\n3 2,3 Hiroyuki Nagai , Kazuhiko Ikeuchi , Takayuki Ogura\n6 6 Takahiro Fukui , Fumimaro Ito , Shin-ichiro Hattori\n1 1 Yuri Furusawa , Atsuhiro Yasuhara , Michiko Ujie\n7 9 Hiroaki Mitsuya , Norio Omagari , Hiroshi Yotsuyanagi\n1 1,10,11, Masaki Imai and Yoshihiro Kawaoka *\n1 Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science,\nThe University of Tokyo, Tokyo 108-8639, Japan; ytsakai@g.ecc.u-tokyo.ac.jp (Y.S.-T.);\nkk187321@stu-cbms.k.u-tokyo.ac.jp (Y.F.); yasuhara@ims.u-tokyo.ac.jp (A.Y.);\nkenken@ims.u-tokyo.ac.jp (K.I.-H.); mimai@ims.u-tokyo.ac.jp (M.I.)\n2 Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science,\nThe University of Tokyo, Tokyo 108-8639, Japan; michiko@ims.u-tokyo.ac.jp (M.K.);\nsaito-id@ims.u-tokyo.ac.jp (M.S.); kikeuchi004@gmail.com (K.I.); yotsudid@ims.u-tokyo.ac.jp (H.Y.)\n3\nScience, The University of Tokyo, Tokyo 108-8639, Japan; e-adachi@ims.u-tokyo.ac.jp (E.A.);\nnagai.hir@gmail.com (H.N.)\n4\n5 Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital,\nTochigi 321-0974, Japan; nichiro4747@gmail.com (I.N.); rie.amechan@gmail.com (R.B.)\n6 Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital,\nTokyo 190-8531, Japan; h.koh@tachikawa-hosp.gr.jp (H.K.); ftakahiro0529@yahoo.co.jp (T.F.);\nﬁto102351@gmail.com (F.I.)\n7 Department of Refractory Viral Infections, National Center for Global Health and Medicine Research\nInstitute, Tokyo 162-8655, Japan; kmaeda@ri.ncgm.go.jp (K.M.); shattori@ri.ncgm.go.jp (S.-i.H.);\nhmitsuya@hosp.ncgm.go.jp (H.M.)\n8 Department of Emergency Medicine and Critical Care Medicine, Saiseikai Utsunomiya Hospital,\nTochigi 321-0974, Japan; alongthelongestway2003@yahoo.co.jp (T.O.); fujitak.727@gmail.com (K.F.)\n9 Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital,\nTokyo 162-8655, Japan; kyamamoto@hosp.ncgm.go.jp (K.Y.); tnakamoto@hosp.ncgm.go.jp (T.N.);\nnohmagari@hosp.ncgm.go.jp (N.O.)\n10\nMadison, WI 53706, USA\n11\nScience, The University of Tokyo, Tokyo 108-8639, Japan\n* Correspondence: yamayo@ims.u-tokyo.ac.jp (S.Y.); yoshihiro.kawaoka@wisc.edu (Y.K.)\nù Academic Editor: Giorgio Pal\nReceived: 12 November 2020; Accepted: 8 December 2020; Published: 10 December 2020\nAbstract:\n/ Viruses 12 2020 , , 1420; doi:10.3390 v12121420\n\n2,3 4 , Michiko Koga , Osamu Akasaka ,\n7 3 2,3 , Eisuke Adachi , Makoto Saito ,\n8 5 8 , Rie Baba , Kensuke Fujita ,\n7 9 9 , Kei Yamamoto , Takato Nakamoto ,\n1 1 1 , Shinya Yamada , Mutsumi Ito ,\n2,3 1 , Kiyoko Iwatsuki-Horimoto ,\nm-ujie@ims.u-tokyo.ac.jp (M.U.); syamada@g.ecc.u-tokyo.ac.jp (S.Y.); ito-mu@ims.u-tokyo.ac.jp (M.I.);\nDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of Institute of Medical\nEmergency Medical Center, Fujisawa City Hospital, Kanagawa 251-8550, Japan; samukun036@gmail.com\nDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison,\nInternational Research Center for Infectious Diseases, Department of Special Pathogens, Institute of Medical\n\u0001\u0002\u0003\u0001\u0004\u0005\u0006\u0007\b\n\u0001\u0002\u0003\u0004\u0005\u0006\u0007\nReverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose\ncoronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local clinics where\nRT-qPCR testing capability is lacking, rapid antigen tests (RATs) for COVID-19 based on lateral ﬂow\nimmunoassays are used for rapid diagnosis. However, their sensitivity compared with each other\nand with RT-qPCR and infectious virus isolation has not been examined. Here, we compared the\nsensitivity among four RATs by using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\nisolates and several types of COVID-19 patient specimens and compared their sensitivity with that\nof RT-qPCR and infectious virus isolation. Although the RATs read the samples containing large\n/ / www.mdpi.com journal viruses",
        "char_count": 4082,
        "word_count": 523,
        "extraction_method": "two_column"
      },
      {
        "page_number": 2,
        "text": "Viruses 12 2020 , , 1420\nare shedding infectious SARS-CoV-2.\nKeywords: rapid antigen test; diagnosis; COVID-19; SARS-CoV-2\n1. Introduction\n1 pathogen in China at the end of 2019 [\ncauses symptoms such as cough and fever, severe pneumonia, and death. The WHO reported that\n// / 16 September 2020 ( https: covid19.who.int\nidentiﬁcation and isolation of patients are required.\nusing nasopharyngeal (N) swabs, throat (T) swabs, or saliva [\nRNA extraction and high-throughput RT-qPCR systems have been developed. Although such tests are\nwidely utilized in public health laboratories and large well-equipped hospitals, they are unavailable\nin local clinics where patients who suspect they have COVID-19 often go ﬁrst. Therefore, specimens\nresult and increases the anxiety of the suspected COVID-19 patients. To improve this situation, rapid\nantigen tests (RATs) for COVID-19, which does not require speciﬁc and expensive machinery, have\nbeen approved for clinical use in Japan and other countries, and the sensitivity of these tests has been\ncompared with that of several kinds of RT-qPCR [\nthe detection of isolated viruses. We also evaluated their e\n2. Materials and Methods\n2.1. Ethics and Biosafety Statements\n1 February 2020). Signed informed consent was obtained from all participants.\n(BSL3) laboratories at the University of Tokyo, which were approved for such use by the Ministry of\nAgriculture, Forestry, and Fisheries, Japan.\n2.2. Cells\nVero cells expressing human serine protease TMPRSS2 (Vero-TMPRSS2) [\nin DMEM containing 10% fetal calf serum (FCS), 1 mg\n/ µ streptomycin, and 5 g\n◦\nat 37 C under 5% CO . We used these cells after clearance of mycoplasma.\n2\n\n2 of 8\namounts of virus as positive, even the most sensitive RAT read the samples containing small amounts\nof virus as negative. Moreover, all RATs tested failed to detect viral antigens in several specimens\nfrom which the virus was isolated. The current RATs will likely miss some COVID-19 patients who\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged as a novel human\n], is responsible for coronavirus disease 2019 (COVID-19), which\nmore than 29 million cases of COVID-19, including approximately 900,000 deaths, have occurred as of\n). To control the spread of SARS-CoV-2 infections, rapid\nThe gold standard for COVID-19 diagnosis is reverse transcription-quantitative PCR (RT-qPCR)\n2 ]. RT-qPCR kits that do not require viral\nneed to be transported to and examined at sites that have RT-qPCR capability, which delays the test\n– ]. Although these RATs might be useful for 3 9\nthe identiﬁcation of COVID-19 patients in local clinics, their sensitivity is important in determining\nusage strategies. Here, we examined the sensitivity of four RATs available in Japan in August 2020 for\nﬀ ectiveness with several kinds of clinical\nspecimens collected from COVID-19 patients and compared it with that of RT-qPCR and virus isolation.\nHuman samples were collected by following protocols approved by the Research Ethics Review\nCommittee of the Institute of Medical Science, the University of Tokyo (approval number 2019-71-0201;\nAll experiments with SARS-CoV-2 were performed prior to 8 September 2020 in biosafety level 3\n] were maintained 10\n/ / / µ mL G418, 100 units mL penicillin, 100 g mL\nmL plasmocin prophylactic (InvivoGen, San Diego, CA, USA) and incubated",
        "char_count": 3353,
        "word_count": 529,
        "extraction_method": "two_column"
      },
      {
        "page_number": 3,
        "text": "Viruses 12 2020 , , 1420\n2.3. Viruses\n/ / / SARS-CoV-2 (UT-NCGM02 Human 2020\n(HP72)] were isolated from clinical samples collected in February and August, respectively, and titrated\nin Vero-TMPRSS2 cells by performing plaque assays [\n2.4. Clinical Samples\n= = n n Gargle lavage ( 7), saliva (\n= N n n nasopharyngeal ( ) swab ( 18), sputum (\n( Supplementary Materials Table S1\naspirate samples were diluted in BD universal viral transport medium if needed. These media were\nused as test specimens. Gargle lavages were examined directly.\n2.5. RT-qPCR\nTokyo, Japan) according to the protocol of the National Institute of Infectious Disease, Japan [\n> value of 40 was considered a negative result.\n2.6. Rapid Antigen Test (RAT)\nThe RATs listed in Table 1\nmanufacturers’ instructions, using 75–7500 plaque formation unit (PFU) of stock virus in 50\nµ of culture supernatant or 50\neach sample.\nTable 1.\nName Manufacturer\nStandard Q COVID-19 Ag SD Biosensor\nEspline SARS-CoV-2 Fujirebio\nQuickNavi -COVID19 Ag Denka Seiken\nImmunoAce SARS-CoV-2 Tauns Laboratories\nThe lysed sample is dropped into the well and the reaction occurs inside a covered plastic body. a\nµ antigen tests (RATs) tested, the test samples (50\nwas then assayed. Input ratios were calculated using the following formula: volume B\nThe time required to obtain the results is based on the manufacturer’s instructions provided with the kit. c\n2.7. Virus Isolation\n◦\nincubated at 37\n/ µ 5% FCS, 10 mM HEPES, 100 g mL gentamicin sulfate, and 2.5\n◦\nﬀ 37 C. The appearance of cytopathic e\n3. Results\n3.1. Comparison of 4 Rapid Antigen Tests (RATs)\nWe evaluated four RATs that were available in Japan in August 2020 (Table\nimmunochromatographic tests; therefore, their sensitivity is dependent on the binding kinetics of\nthe monoclonal antibodies used in each RAT. The composition of the lysis bu\nof specimen in the analyte, and the method used to visualize the result also a\nAs a result that the manufacturers do not disclose the composition of the lysis bu\n\n3 of 8\n/ / / Tokyo (NC02) and UT-HP072 Human 2020 Tokyo\n11 ].\n= = n n 27), throat (T) swab ( 2), nasal vestibule swab ( 1),\n= = n 4), and tracheal aspirate ( 17) samples\n) were collected from COVID-19 patients at several timepoints\nafter onset. Swabs were soaked in BD universal viral transport medium; saliva, sputum, and tracheal\nViral RNA was isolated from the specimens by using the QIAamp Viral RNA Mini Kit (QIAGEN,\nTokyo, Japan). One step RT-qPCR was performed using the LightCycler 96 System (Roche Diagnostics,\n12 ]. A Cq\nwere evaluated according to the procedures described in the\nµ L\nL of specimen. Two independent experiments were performed with\nRapid antigen tests examined in this study.\nMethod for Input Ratio Country of Minutes to\n(%) a b c Visualization Assess Manufacture\nColor particle 14.3 15–30 Korea\nAlkaline phosphatase 10.0 30 Japan\nColor latex 12.5 15 Japan\nPlatinum-gold colloid 28.6 15 Japan\nFor all rapid b\nﬀ L) were mixed with lysis bu er (A). A part of the lysed sample (B)\n× / + µ (50 L volume A) 100.\nThe specimens were inoculated into Vero-TMPRSS2 cells in 24 well-plates and the cells were\nC for 1 h. After removal of the inoculum, the cells were incubated in DMEM containing\n/ µ g mL amphotericin B for 6 days at\nects was checked for 6 days at least once a day.\n1 ). These RATs are\nﬀ er, the proportion\nﬀ ect the sensitivity.\nﬀ er, we could not",
        "char_count": 3390,
        "word_count": 595,
        "extraction_method": "two_column"
      },
      {
        "page_number": 4,
        "text": "Viruses 12 2020 , , 1420\nﬀ compare this parameter. The amount of lysis bu\nﬀ di ered among the RATs tested. Accordingly, the percentages of the specimens used also di\nfor Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce\n(Table 1 ). The method for visualization of the results also di\nQ COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce SARS-CoV-2\nrespectively, to visualize the antigen-antibody immune-complexes. The visualized results are assessed\nby the human eye at 15–30, 30, 15, and 15 min, respectively, after adding the analyte. Although the\n(see the footnote to Tables 2 and 3 ).\nTable 2.\nNumber of Standard Q RT-qPCR\na Samples COVID-19 Ag (Cq Value)\nb –20.0 4 4\n20.0–22.5 7 7\n22.5–25.0 17 10.5\n25.0–27.5 20 2.5\n27.5–30.0 17 2\n30.0– 11 0\na\nb 4 sputum, and 17 tracheal aspirates were examined.\nwhen a kit identiﬁed a sample as positive in both tests, a value of 1 was assigned. If only one test was positive, a\nvalue of 0.5 was assigned. If both tests were negative, a value of 0 was assigned.\nthe virus was isolated.\nTable 3. Sensitivity of rapid antigen tests for di\nNumber of Standard Q RT-qPCR\nClinical Specimen\nSamples COVID-19 Ag (Cq Value)\na Gargle lavage 7 26.3–36.0 0\nSaliva 27 18.8–33.0 10\nc 25.8 T Swab 2 , 33.6 0\nNasal vestibule swab 1 34.8 0\nN swab 18 19.7-33.0 8\nSputum 4 19.9-34.3 1\nTracheal aspirate 17 19.6-35.6 7\na\nb negative, a value of 0 was assigned.\nthis specimen.\n3.2. Sensitivity of RATs for Two Isolated SARS-CoV-2 Strains\nwere diluted to the indicated PFU and then examined by RT-qPCR to determine the Cq value of each\nand 16.9, 17.8, 18.8, 20.4, 21.1, 22.7, and 24.0 at 7500, 5000, 2500, 750, 500, 250, and 75 PFU of HP72\n(Table S2). Standard Q COVID-19 Ag and ImmunoAce SARS-CoV-2 detected as little as 250 PFU of\nNC02, respectively (Table S2). Standard Q COVID-19 Ag and Espline SARS-CoV-2 detected as little as\n250 PFU of HP72, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 detected 5000 PFU\nﬀ ImmunoAce SARS-CoV-2 di ered depending on the isolate.\n\n4 of 8\n/ ﬀ er and specimen lysis bu er mixture used for testing\nﬀ ered:\nSARS-CoV-2, the percentages of specimens used were 14.3%, 10.0%, 12.5%, and 28.6%, respectively\nﬀ ered among these tests in that Standard\nuse color particles, alkaline phosphatase and its substrate, color latex, and platinum-gold colloids,\ntypes of specimens recommended for all four RATs are N swabs, we tested other types of specimens\nSensitivity of rapid antigen tests for clinical specimens.\nQuickNavi ImmunoAce Virus Espline\nCOVID19 Ag SARS-CoV-2 Isolation SARS-CoV-2\nc 4 3.5 3.5 2\n7 4.5 6 6\n12.5 5 9.5 9\n3 2 3.5 4\n1 0 2 3\n0 0 0 0\nA total of 76 clinical specimens including 7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs,\nEach sample was tested in two independent experiments;\nc Number of samples from which\nﬀ erent types of clinical specimen.\nQuickNavi ImmunoAce Virus Espline\nCOVID19 Ag SARS-CoV-2 Isolation SARS-CoV-2\nb 0 0 0 0\n12 5 13 12\n0 0 0 1\n0 0 0 0\n8 3.5 7 10\n1 1 1 0\n6.5 5.5 3.5 1\nEach specimen was tested in two independent experiments; when a kit identiﬁed a sample as positive in both\ntests, a value of 1 was assigned. If only one test was positive, a value of 0.5 was assigned. If both tests were\nc Number of samples from which virus was isolated. Virus was isolated from\nTo compare the sensitivity of these four RATs, two SARS-CoV-2 isolate stocks (NC02 and HP72)\nsample. The Cq values were 18.0, 21.7, 22.2, 23.1, and 25.4 at 7500, 750, 500, 250, and 75 PFU of NC02\nNC02, whereas Espline SARS-CoV-2 and QuickNavi -COVID19 Ag detected 500 PFU and 750 PFU of\nof HP72. These results show that the sensitivity for virus detection of Standard Q COVID-19 Ag and\nEspline SARS-CoV-2 was better than that of QuickNavi COVID19 Ag, and that virus detection by",
        "char_count": 3816,
        "word_count": 689,
        "extraction_method": "two_column"
      },
      {
        "page_number": 5,
        "text": "Viruses 12 2020 , , 1420\n3.3. Sensitivity of RATs for Clinical Specimens\n(T) swabs, 1 nasal vestibule swabs, 18 nasopharyngeal (N) swabs, 4 sputum, and 17 tracheal aspirates\nwere collected and their viral genomic RNA levels were examined by RT-qPCR. These 76 clinical\nRATs and subjected to virus isolation using Vero-TMPRSS2 cells (Table\nQ COVID-19 Ag and Espline SARS-CoV-2 detected viral antigens in all specimens with Cq values\nlower than 22.5, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 failed to detect\nthe sensitivity was on the order of Espline SARS-CoV-2, Standard Q COVID-19 Ag, ImmunoAce\nSARS-CoV-2, and QuickNavi COVID19 Ag (Table\nvalue greater than 25.0, the sensitivity of these four RATs was similar. These results indicate that the\nImmunoAce SARS-CoV-2; QuickNavi -COVID19 Ag had the lowest sensitivity.\nof days after onset that the specimens were obtained, and the Cq values of the RT-qPCR (Figure\nﬃ Although all of the RATs e\nﬀ results from the RATs could be di\nRAT-positive, whereas others were RAT-negative). Several specimens with Cq values higher than those\ncyan arrows in Figure 1\nﬀ protein content may have di\ninhibitors or enhancers for the antigen-antibody reaction of the RATs. Importantly, several specimens\nfrom which the virus was isolated were negative with all RATs tested, indicating that these RATs could\npotentially fail to diagnose patients shedding infectious SARS-CoV-2.\nFigure 1.\nand 17 tracheal aspirates) were examined by Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi\nCOVID19 Ag, and ImmunoAce SARS-CoV-2. Two independent experiments were performed.\n\n5 of 8\nTo evaluate the sensitivity of the four RATs for clinical specimens, 7 gargle lavages, 27 saliva, 2 throat\nspecimens, which were divided into 6 groups based on their Cq value, were examined in the four\n2 and Table S1). Standard\nviral antigens in several of these specimens. For specimens with a Cq value between 22.5 and 25.0,\n2 and Table S1). For the specimens with a Cq\nsensitivity of the four RATs is lower than that of RT-qPCR but similar to that of virus isolation. Overall,\nthe sensitivity of Espline SARS-CoV-2 and Standard Q COVID-19 Ag was slightly better than that of\nWe next plotted the results from the RATs and virus isolation, in accordance with the number\n1 ).\nciently detected viral antigens in the specimens with low Cq values, the\nerent for two specimens with similar Cq values (i.e., some were\nof specimens that were RAT-negative, but with the above-described low Cq values (as indicated by\n) were found to be RAT-positive. These results suggest that the viral RNA and\nered between the specimens or that some samples may have contained\nResults of RATs plotted based on the Cq value of RT-qPCR and days after onset. Viral antigens in\n76 clinical specimens (7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs, 4 sputum,",
        "char_count": 2878,
        "word_count": 472,
        "extraction_method": "two_column"
      },
      {
        "page_number": 6,
        "text": "Viruses 12 2020 , , 1420\nspecimens from which virus was isolated; open black circles indicate specimens from which virus was\none was positive, no color indicates both were negative.\nﬀ Since the type of specimen likely a\nand nasal vestibule swabs showed higher Cq values than the other types of specimens (Table\nAll four RATs detected virus antigens in one sputum sample, although no virus was isolated from\nand 1 nasal vestibule swabs, although the virus was isolated from one T swab sample. Since N swabs\nand saliva are suitable specimens for diagnosis in clinics, we plotted the results from the RATs and\nvirus isolation based on the number of days after onset that the specimens were collected and the Cq\nvalues of the RT-qPCR (Figure 2\nﬃ SARS-CoV-2 e\nthat were collected at early timepoints after onset.\nFigure 2.\nand days after onset. The results from the N swabs and saliva samples were extracted from Figure\n\n6 of 8\nAll specimens were also tested by RT-qPCR and subjected to virus isolation. Open red circles indicate\nnot isolated. Circles ﬁlled in black indicate both results were positive, those ﬁlled in gray indicate that\nects the sensitivity of RATs, we assessed our results according\nto specimen type (gargle lavage, saliva, T swab, nasal vestibule swab, N swab, sputum, and tracheal\naspirate). Although the Cq value varied between specimens from 18.8 to 36.0, gargle lavage, T swabs,\n3 ).\n4 sputum samples tested. All four RATs failed to detect virus antigens in all 7 gargle lavages, 2 T swabs,\n). Standard Q COVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce\n< ciently detected virus antigens in N swabs and saliva with low Cq values (Cq 25)\nResults of RATs using N swabs and saliva specimens plotted based on the Cq value of RT-qPCR\n1 .",
        "char_count": 1749,
        "word_count": 302,
        "extraction_method": "two_column"
      },
      {
        "page_number": 7,
        "text": "Viruses 12 2020 , , 1420\n4. Discussion\nSARS-CoV-2 and QuickNavi COVID19 Ag. For specimens such as saliva and swabs, Standard Q\nThese three kits detected viral antigens in more than half of the specimens whose Cq values of RT-qPCR\nwere less than approximately 25. Therefore, these RATs may be suitable for the detection of COVID-19\npatients with a high likelihood of transmitting the virus to others.\nThis ﬁnding indicates that the current RATs are likely to miss some COVID-19 patients who are\nvirus to others. Further studies are required to address this point. In addition, the present study used\nﬀ bu\nisolated gave negative results with all of the RATs tested here. Nonetheless, these RATs need to be\nimproved with respect to their sensitivity.\nrates of these kits. Therefore, studies on false-positive rates should be performed in the future to\ndetermine the speciﬁcity of these and other RATs.\nSupplementary Materials: The following are available online at\nTable S1: List of specimens and results, Table S2: Sensitivity of rapid antigen tests for stock viruses.\nAuthor Contributions:\n(Seiya Yamayoshi) and Y.K. analyzed the data. S.Y. (Seiya Yamayoshi) and Y.K. wrote the manuscript. All authors\nhave read and agreed to the published version of the manuscript.\nFunding:\nJP20nk0101614, and JP20nk0101603), the Japan Initiative for Global Research Network on Infectious\nDiseases (J-GRID) (JP19fm0108006), and a Japan Program for Infectious Diseases Research and Infrastructure\n(JP20wm0125002) from the Japan Agency for Medical Research and Development (AMED), and the National\nHHSN272201400008C).\nAcknowledgments:\nof experiments and Susan Watson for editing the manuscript.\nConﬂicts of Interest:\nReferences\n1.\nN. Engl. J. Med. from Patients with Pneumonia in China, 2019.\nSethuraman, N.; Jeremiah, S.S.; Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. 2.\n2249–2251. [ CrossRef ] [ PubMed ]\n3.\nJ. Clin. Microbiol. Antigen Test to Diagnose COVID-19.\n\n7 of 8\nHere we evaluated the sensitivity of four RATs available in Japan in August 2020. The overall\nsensitivity of Standard Q COVID-19 Ag and Espline SARS-CoV-2 was better than that of ImmunoAce\nCOVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce SARS-CoV-2 had similar detection sensitivities.\nin individuals who are shedding a large amount of SARS-CoV-2; that is, they may be useful to identify\nAll four RATs failed to detect viral antigens in several specimens from which virus was isolated.\nshedding infectious SARS-CoV-2. However, it is unclear to what extent such patients would transmit\nswab specimens that were soaked in transport medium; if the specimens were directly soaked in lysis\ner, the sensitivity of the RATs might be improved. The recommended samples for these RATS\nare nasopharyngeal swabs not saliva, and some of the saliva samples from which SARS-CoV-2 was\nIn this study, we focused on the sensitivity of four RATs; we did not evaluate the false-positive\n// / / / / / http: www.mdpi.com 1999-4915 12 12 1420 s1 ,\nS.Y. (Seiya Yamayoshi) and Y.K. designed the study. S.Y. (Seiya Yamayoshi) and Y.S.-T.\nperformed the experiments. M.K., H.M., O.A., I.N., H.K., K.M., E.A., M.S., H.N., K.I., T.O., R.B., K.F., T.F., F.I., S.-i.H.,\nK.Y., T.N., Y.F., N.O., H.M., and H.Y. collected the clinical samples. A.Y., M.U., and S.Y. (Shinya Yamada) assisted\nwith the experiments. M.I. (Mutsumi Ito), K.I.-H., and M.I. (Masaki Imai) assisted with the sample collection. S.Y.\nThis work was supported by a Research Program on Emerging and Re-emerging Infectious\nDiseases (JP19fk0108113 and JP19fk0108166), a Project Promoting Support for Drug Discovery (JP20nk0101612,\nInstitutes of Allergy and Infectious Diseases funded Center for Research on Inﬂuenza Pathogenesis (CRIP;\nWe thank Noriko Kinoshita, Shigehiro Hagiwara, Daisuke Arai, Hidenori Takahashi, Genta\nNagao, and Shunichiro Konishi, Hiroko Shibata, Osamu Takahashi, Takashi Momoda, Hiromi Isshiki for assistance\nYoshihiro Kawaoka obtained funds to organize a symposium, “Inﬂuenza and Other\nInfections” in 2019 from TAUNS Laboratories, Inc. Kei Yamamoto has received grant support from Fujirebio, Inc.\nZhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus\n382 2020 , , 727–733. [ CrossRef ] [ PubMed ]\nJAMA 323 2020 , ,\nNagura-Ikeda, M.; Imai, K.; Tabata, S.; Miyoshi, K.; Murahara, N.; Mizuno, T.; Horiuchi, M.; Kato, K.; Imoto, Y.;\nIwata, M.; et al. Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR\n(RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Ampliﬁcation, and a Rapid\n58 2020 , , e01438-20. [ CrossRef ] [ PubMed ]",
        "char_count": 4669,
        "word_count": 720,
        "extraction_method": "two_column"
      },
      {
        "page_number": 8,
        "text": "Viruses 12 2020 , , 1420\n4.\nrapid antigen test for detection of SARS-CoV-2 virus.\nﬀ Lambert-Niclot, S.; Cu 5.\nﬀ Le Go\nJ. Clin. Microbiol. 2020 in Nasopharyngeal Swabs. ,\n6.\nInt. J. Infect. Dis. 99 2020 in respiratory samples. ,\n7.\nperformance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.\n129 , 104455. [ CrossRef ] [ PubMed ]\n8.\nﬀ Melin, P.; Sto\nFront. Med. (Lausanne) Assay in a Pandemic Context.\n9.\na laboratory without access to molecular methods: Experiences of a general hospital.\n104472. [ CrossRef ] [ PubMed ]\n10.\nKato, F.; et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.\n117 2020 , , 7001–7003. [ CrossRef ] [ PubMed ]\n11.\nProc. Natl. Acad. Sci. USA countermeasure development.\n12.\nJpn. J. Infect. Dis. 73 2020 in Japan. , , 304–307. [\nPublisher’s Note:\nﬃ a liations.\n©\n// (CC BY) license (http:\n\n8 of 8\nMak, G.C.; Cheng, P.K.; Lau, S.S.; Wong, K.K.; Lau, C.S.; Lam, E.T.; Chan, R.C.; Tsang, D.N. Evaluation of\nJ. Clin. Virol. 129 2020 , , 104500. [ CrossRef ] [ PubMed ]\nel, A.; Le Pape, S.; Vauloup-Fellous, C.; Morand-Joubert, L.; Roque-Afonso, A.M.;\n, J.; Delaugerre, C. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen\n58 , e00977-20. [ CrossRef ] [ PubMed ]\nPorte, L.; Legarraga, P.; Vollrath, V.; Aguilera, X.; Munita, J.M.; Araos, R.; Pizarro, G.; Vial, P.; Iruretagoyena, M.;\nDittrich, S.; et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2\n, 328–333. [ CrossRef ] [ PubMed ]\nScohy, A.; Anantharajah, A.; Bodeus, M.; Kabamba-Mukadi, B.; Verroken, A.; Rodriguez-Villalobos, H. Low\nJ. Clin. Virol. 2020 ,\nMertens, P.; De Vos, N.; Martiny, D.; Jassoy, C.; Mirazimi, A.; Cuypers, L.; Van den Wijngaert, S.; Monteil, V.;\nels, K.; et al. Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic\n7 2020 , , 225. [ CrossRef ] [ PubMed ]\nBlairon, L.; Wilmet, A.; Beukinga, I.; Tre-Hardy, M. Implementation of rapid SARS-CoV-2 antigenic testing in\nJ. Clin. Virol. 129 2020 , ,\nMatsuyama, S.; Nao, N.; Shirato, K.; Kawase, M.; Saito, S.; Takayama, I.; Nagata, N.; Sekizuka, T.; Katoh, H.;\nProc. Natl. Acad. Sci. USA\nImai, M.; Iwatsuki-Horimoto, K.; Hatta, M.; Loeber, S.; Halfmann, P.J.; Nakajima, N.; Watanabe, T.; Ujie, M.;\nTakahashi, K.; Ito, M.; et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and\n117 2020 , , 16587–16595. [ CrossRef ] [ PubMed ]\nShirato, K.; Nao, N.; Katano, H.; Takayama, I.; Saito, S.; Kato, F.; Katoh, H.; Sakata, M.; Nakatsu, Y.; Mori, Y.;\net al. Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019)\nCrossRef ] [ PubMed ]\nMDPI stays neutral with regard to jurisdictional claims in published maps and institutional\n2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access\narticle distributed under the terms and conditions of the Creative Commons Attribution\n/ / / / creativecommons.org licenses by 4.0 ).",
        "char_count": 2979,
        "word_count": 502,
        "extraction_method": "two_column"
      }
    ]
  }
}